Longitude (Cayman)’s Amicus Therapeutics FOLD Stock Holding History

Longitude (Cayman)’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,000	Closed	-$209K	–	72
2022 Q3	$209K	Sell	20,000 -60,500	-75%	-$674K	0.33%	52
2022 Q2	$865K	Buy	80,500 +54,500	+210%	+$449K	1.28%	25
2022 Q1	$246K	Buy	+26,000	New	+$244K	0.23%	44
2021 Q3	–	Sell	-250,000	Closed	-$2.41M	–	53
2021 Q2	$2.41M	Buy	250,000 +11,400	+5%	+$111K	1.14%	31
2021 Q1	$2.36M	Buy	+238,600	New	+$3.69M	0.9%	38

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Longitude (Cayman)'s FOLD Position: Q4 2022 in Review

Longitude (Cayman) sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 25,000 shares — an estimated $261K sold.

Longitude (Cayman) first reported a position in FOLD in Q4 2020 and held it in 7 quarters. The position peaked at $2.74M in Q4 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Longitude (Cayman) reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Longitude (Cayman) sold 25,000 Amicus Therapeutics shares in Q4 2022, an estimated $261K.
Longitude (Cayman) first reported a position in Amicus Therapeutics in Q4 2020 and held it in 7 quarters.
Longitude (Cayman)'s Amicus Therapeutics position peaked at $2.74M in Q4 2021.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Longitude (Cayman)'s 13F filing for Q4 2022, filed 6 Feb 2023.